Cargando…
Cross-Modality Imaging of Murine Tumor Vasculature—a Feasibility Study
Tumor vasculature and angiogenesis play a crucial role in tumor progression. Their visualization is therefore of utmost importance to the community. In this proof-of-principle study, we have established a novel cross-modality imaging (CMI) pipeline to characterize exactly the same murine tumors acro...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578087/ https://www.ncbi.nlm.nih.gov/pubmed/34101107 http://dx.doi.org/10.1007/s11307-021-01615-y |
_version_ | 1784596201947004928 |
---|---|
author | Zopf, Lydia M. Heimel, Patrick Geyer, Stefan H. Kavirayani, Anoop Reier, Susanne Fröhlich, Vanessa Stiglbauer-Tscholakoff, Alexander Chen, Zhe Nics, Lukas Zinnanti, Jelena Drexler, Wolfgang Mitterhauser, Markus Helbich, Thomas Weninger, Wolfgang J. Slezak, Paul Obenauf, Anna Bühler, Katja Walter, Andreas |
author_facet | Zopf, Lydia M. Heimel, Patrick Geyer, Stefan H. Kavirayani, Anoop Reier, Susanne Fröhlich, Vanessa Stiglbauer-Tscholakoff, Alexander Chen, Zhe Nics, Lukas Zinnanti, Jelena Drexler, Wolfgang Mitterhauser, Markus Helbich, Thomas Weninger, Wolfgang J. Slezak, Paul Obenauf, Anna Bühler, Katja Walter, Andreas |
author_sort | Zopf, Lydia M. |
collection | PubMed |
description | Tumor vasculature and angiogenesis play a crucial role in tumor progression. Their visualization is therefore of utmost importance to the community. In this proof-of-principle study, we have established a novel cross-modality imaging (CMI) pipeline to characterize exactly the same murine tumors across scales and penetration depths, using orthotopic models of melanoma cancer. This allowed the acquisition of a comprehensive set of vascular parameters for a single tumor. The workflow visualizes capillaries at different length scales, puts them into the context of the overall tumor vessel network and allows quantification and comparison of vessel densities and morphologies by different modalities. The workflow adds information about hypoxia and blood flow rates. The CMI approach includes well-established technologies such as magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), and ultrasound (US), and modalities that are recent entrants into preclinical discovery such as optical coherence tomography (OCT) and high-resolution episcopic microscopy (HREM). This novel CMI platform establishes the feasibility of combining these technologies using an extensive image processing pipeline. Despite the challenges pertaining to the integration of microscopic and macroscopic data across spatial resolutions, we also established an open-source pipeline for the semi-automated co-registration of the diverse multiscale datasets, which enables truly correlative vascular imaging. Although focused on tumor vasculature, our CMI platform can be used to tackle a multitude of research questions in cancer biology. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11307-021-01615-y. |
format | Online Article Text |
id | pubmed-8578087 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-85780872021-11-15 Cross-Modality Imaging of Murine Tumor Vasculature—a Feasibility Study Zopf, Lydia M. Heimel, Patrick Geyer, Stefan H. Kavirayani, Anoop Reier, Susanne Fröhlich, Vanessa Stiglbauer-Tscholakoff, Alexander Chen, Zhe Nics, Lukas Zinnanti, Jelena Drexler, Wolfgang Mitterhauser, Markus Helbich, Thomas Weninger, Wolfgang J. Slezak, Paul Obenauf, Anna Bühler, Katja Walter, Andreas Mol Imaging Biol Research Article Tumor vasculature and angiogenesis play a crucial role in tumor progression. Their visualization is therefore of utmost importance to the community. In this proof-of-principle study, we have established a novel cross-modality imaging (CMI) pipeline to characterize exactly the same murine tumors across scales and penetration depths, using orthotopic models of melanoma cancer. This allowed the acquisition of a comprehensive set of vascular parameters for a single tumor. The workflow visualizes capillaries at different length scales, puts them into the context of the overall tumor vessel network and allows quantification and comparison of vessel densities and morphologies by different modalities. The workflow adds information about hypoxia and blood flow rates. The CMI approach includes well-established technologies such as magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), and ultrasound (US), and modalities that are recent entrants into preclinical discovery such as optical coherence tomography (OCT) and high-resolution episcopic microscopy (HREM). This novel CMI platform establishes the feasibility of combining these technologies using an extensive image processing pipeline. Despite the challenges pertaining to the integration of microscopic and macroscopic data across spatial resolutions, we also established an open-source pipeline for the semi-automated co-registration of the diverse multiscale datasets, which enables truly correlative vascular imaging. Although focused on tumor vasculature, our CMI platform can be used to tackle a multitude of research questions in cancer biology. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11307-021-01615-y. Springer International Publishing 2021-06-08 2021 /pmc/articles/PMC8578087/ /pubmed/34101107 http://dx.doi.org/10.1007/s11307-021-01615-y Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Zopf, Lydia M. Heimel, Patrick Geyer, Stefan H. Kavirayani, Anoop Reier, Susanne Fröhlich, Vanessa Stiglbauer-Tscholakoff, Alexander Chen, Zhe Nics, Lukas Zinnanti, Jelena Drexler, Wolfgang Mitterhauser, Markus Helbich, Thomas Weninger, Wolfgang J. Slezak, Paul Obenauf, Anna Bühler, Katja Walter, Andreas Cross-Modality Imaging of Murine Tumor Vasculature—a Feasibility Study |
title | Cross-Modality Imaging of Murine Tumor Vasculature—a Feasibility Study |
title_full | Cross-Modality Imaging of Murine Tumor Vasculature—a Feasibility Study |
title_fullStr | Cross-Modality Imaging of Murine Tumor Vasculature—a Feasibility Study |
title_full_unstemmed | Cross-Modality Imaging of Murine Tumor Vasculature—a Feasibility Study |
title_short | Cross-Modality Imaging of Murine Tumor Vasculature—a Feasibility Study |
title_sort | cross-modality imaging of murine tumor vasculature—a feasibility study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578087/ https://www.ncbi.nlm.nih.gov/pubmed/34101107 http://dx.doi.org/10.1007/s11307-021-01615-y |
work_keys_str_mv | AT zopflydiam crossmodalityimagingofmurinetumorvasculatureafeasibilitystudy AT heimelpatrick crossmodalityimagingofmurinetumorvasculatureafeasibilitystudy AT geyerstefanh crossmodalityimagingofmurinetumorvasculatureafeasibilitystudy AT kavirayanianoop crossmodalityimagingofmurinetumorvasculatureafeasibilitystudy AT reiersusanne crossmodalityimagingofmurinetumorvasculatureafeasibilitystudy AT frohlichvanessa crossmodalityimagingofmurinetumorvasculatureafeasibilitystudy AT stiglbauertscholakoffalexander crossmodalityimagingofmurinetumorvasculatureafeasibilitystudy AT chenzhe crossmodalityimagingofmurinetumorvasculatureafeasibilitystudy AT nicslukas crossmodalityimagingofmurinetumorvasculatureafeasibilitystudy AT zinnantijelena crossmodalityimagingofmurinetumorvasculatureafeasibilitystudy AT drexlerwolfgang crossmodalityimagingofmurinetumorvasculatureafeasibilitystudy AT mitterhausermarkus crossmodalityimagingofmurinetumorvasculatureafeasibilitystudy AT helbichthomas crossmodalityimagingofmurinetumorvasculatureafeasibilitystudy AT weningerwolfgangj crossmodalityimagingofmurinetumorvasculatureafeasibilitystudy AT slezakpaul crossmodalityimagingofmurinetumorvasculatureafeasibilitystudy AT obenaufanna crossmodalityimagingofmurinetumorvasculatureafeasibilitystudy AT buhlerkatja crossmodalityimagingofmurinetumorvasculatureafeasibilitystudy AT walterandreas crossmodalityimagingofmurinetumorvasculatureafeasibilitystudy |